The Need for PAN-TB

Overview of TB

What is tuberculosis?

Tuberculosis, or TB, is a contagious disease caused by a bacterial strain called Mycobacterium tuberculosis (M.tb). It usually affects the lungs but can spread to other parts of the body. The disease can spread easily through the air when an infected person coughs, sneezes or talks, a form known as active TB, especially in crowded areas.

What is tuberculosis?

But not everyone who contracts TB will develop active TB symptoms. Some people will harbor the bacteria without becoming ill. This is called latent TB, and it can be challenging to diagnose, as it doesn’t show any symptoms. However, those with latent TB can still develop active TB later in life, especially if their immune system becomes weak, making it critical to diagnose and treat latent TB as well.

 

Global TB Snapshot

Tuberculosis (TB) is the world’s deadliest infectious disease.In 2024, an estimated 10.7 million people fell ill with TB and 1.23 million died, including 150,000 people living with HIV, according to the WHO Global Tuberculosis Report 2025. 

Global TB Snapshot

Despite progress, significant gaps remain in diagnosing and treating TB. In 2024, only 78% of people who developed TB (8.3 million) were diagnosed and reported, leaving millions without a diagnosis or access to appropriate treatment. An estimated 390,000 people also developed drug-resistant TB, which is more difficult to treat. 

Global efforts have saved an estimated 83 million lives since 2000, but progress remains off track to meet the UN Sustainable Development Goal of ending the TB epidemic by 2030. Continued investment in research, innovation, and access to effective tools is essential to accelerate progress and save more lives. 

 

Potential Impact of a PAN-TB Regimen

A pan-TB regimen that could treat both drug-susceptible and drug-resistant TB in three months or less – significantly shorter than current standard TB treatments – would allow more TB patients to be cured, resulting in less transmission of infection and a reduced burden on health systems that treat TB. In turn, this would permit more resources to be focused on finding the estimated 2.4 million cases of active TB that are often underreported and go undiagnosed and untreated every year. 

Looking further ahead, PAN-TB partners aim to make treatment simpler still. One possibility is a long-acting injectable (LAI) formulation of a future pan-TB regimen that could reduce months of daily medicines to just one or a small number of doses over the full course of treatment. 

This work could result in a significant global health impact, with an accelerated decline in TB disease burden that ultimately paves the path to eliminating TB.